Author

N. Roth

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 2 Animal Behavior & Cognition· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:mouse· 6 Research Focus:drug response / drug discovery· 4 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:rat· 2 Assay:behavioral assay· 1

Frequent Co-Authors

S. Rauch· 7 shared B. Petsch· 5 shared D. Hoffmann· 4 shared S. O. Mueller· 4 shared A. Dorhoi· 3 shared B. Corleis· 3 shared C. Fricke· 3 shared J. Gergen· 3 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

S. Rauch

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Dissecting the Complexities of Learning With Infinite Hidden Markov Models

S. A. Bruijns, International Brain Laboratory, K. Bougrova, I. C. Laranjeira, P. Y. P. Lau, G. T. Meijer, N. J. Miska, J.-P. Noel, A. Pan-Vazquez, N. Roth, K. Z. Socha, A. E. Urai, P. Dayan

The paper introduces an infinite hidden semi-Markov model to analyze learning curves in mice, finding three major learning stages and behavior changes after rest periods.

bioRxiv · Dec 22, 2023 · PreprintAnimal Behavior & Cognition

Assessment of Immunogenicity and Efficacy of CV0501 mRNA-based Omicron COVID-19 Vaccination in Small Animal Models

N. Roth, J. Gergen, K. Kovacikova, S. Mueller, L. Ulrich, J. Schoen, N. J. Halwe, C. Fricke, B. Corleis, A. Dorhoi, D. Hoffmann, M. Beer, D. Maione, B. W. Petsch, S. Rauch

This paper evaluates the immunogenicity and efficacy of a bivalent mRNA vaccine CV0501 against Omicron subvariants in animal models, showing robust neutralizing antibodies and reduced viral loads.

bioRxiv · Jan 4, 2023Immunology

Extracellular ATP drives pancreatic cancer cell invasion via purinergic receptor-integrin interactions

E. Tomas Bort, M. Joseph, Q. Wang, E. Carter, N. Roth, J. Gibson, A. Samadi, H. Kocher, S. Simoncelli, P. J. McCormick, R. P. Grose

This study identifies P2RY2 as a key purinergic receptor involved in pancreatic cancer invasion through interactions with integrins, suggesting therapeutic targeting potential.

bioRxiv · Oct 24, 2022Cancer Biology

Low-dose bivalent mRNA vaccine is highly effective against different SARS-CoV-2 variants in a transgenic mouse model

B. Corleis, D. Hoffmann, S. Rauch, C. Fricke, N. Roth, J. Gergen, K. Kovacikova, K. Schlottau, N. J. Halwe, L. Ulrich, J. Schön, K. Wernike, M. Widera, S. Ciesek, S. O. Mueller, , A. Dorhoi

This study shows a low-dose bivalent mRNA vaccine targeting multiple SARS-CoV-2 variants provides strong protection in mice and rats, with comparable antibody levels and reduced viral replication.

bioRxiv · Apr 20, 2022 · PreprintImmunology

mRNA Vaccines Induce Rapid Antibody Responses in Mice

M. Gebre, S. Rauch, N. Roth, J. Gergen, J. Yu, X. Liu, A. Cole, S. Mueller, B. W. Petsch, D. H. Barouch

This study shows mRNA vaccines induce rapid antibody responses in mice by day 5, outperforming DNA, protein, and adenovirus vaccines for SARS-CoV-2 and HIV-1 antigens.

bioRxiv · Nov 1, 2021Microbiology

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

M. Gebre, S. Rauch, N. Roth, J. Yu, A. Chandrashekar, N. Mercado, X. He, J. Liu, K. McMahan, A. Martinot, T. Giffin, D. Hope, S. Patel, D. Sellers, O. Sanborn, , D. H. Barouch

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

bioRxiv · Aug 13, 2021 · PreprintImmunology

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

N. Roth, J. Schoen, D. Hoffmann, M. Thran, A. Thess, S. O. Mueller, B. Petsch, S. Rauch

This study compares two mRNA vaccines, CVnCoV and CV2CoV, showing CV2CoV induces higher neutralizing antibody titers and cross-neutralization against variants in rats.

bioRxiv · May 13, 2021 · PreprintImmunology

CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2

D. Hoffmann, B. Corleis, S. Rauch, N. Roth, J. Muehe, N. J. Halwe, L. Ulrich, C. Fricke, J. Schoen, A. Kraft, A. Breithaupt, K. Wernike, A. Michelitsch, F. Sick, C. Wylezich, , M. Beer

This study evaluates the efficacy of the CVnCoV mRNA vaccine against ancestral and emerging SARS-CoV-2 variants in a human ACE2 transgenic mouse model, showing complete protection against B.1.351.

bioRxiv · Mar 22, 2021Microbiology

mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents

S. Rauch, N. Roth, K. Schwendt, M. Fotin-Mleczek, S. O. Mueller, B. Petsch

This study shows that the mRNA vaccine CVnCoV induces strong neutralizing antibodies and protects hamsters from SARS-CoV-2 infection.

bioRxiv · Oct 23, 2020Immunology